Perceptive Advisors LLC trimmed its holdings in shares of AnaptysBio Inc (NASDAQ:ANAB) by 23.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 756,387 shares of the biotechnology company’s stock after selling 225,882 shares during the quarter. AnaptysBio comprises 2.5% of Perceptive Advisors LLC’s portfolio, making the stock its 8th biggest holding. Perceptive Advisors LLC owned 3.22% of AnaptysBio worth $76,183,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the business. Two Sigma Securities LLC acquired a new position in AnaptysBio during the fourth quarter worth $212,000. Goldman Sachs Group Inc. increased its position in AnaptysBio by 39.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 149,567 shares of the biotechnology company’s stock worth $15,065,000 after buying an additional 42,004 shares during the last quarter. Deutsche Bank AG increased its position in AnaptysBio by 83.6% during the fourth quarter. Deutsche Bank AG now owns 192,361 shares of the biotechnology company’s stock worth $19,373,000 after buying an additional 87,566 shares during the last quarter. Franklin Resources Inc. increased its position in AnaptysBio by 16.6% during the fourth quarter. Franklin Resources Inc. now owns 325,600 shares of the biotechnology company’s stock worth $32,794,000 after buying an additional 46,400 shares during the last quarter. Finally, Fred Alger Management Inc. acquired a new position in AnaptysBio during the fourth quarter worth $453,000. 99.25% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently issued reports on ANAB. Royal Bank of Canada raised their price target on AnaptysBio to $144.00 and gave the company an “outperform” rating in a research report on Friday, March 2nd. Wedbush reissued an “outperform” rating and set a $142.00 target price on shares of AnaptysBio in a research report on Tuesday, February 20th. Jefferies Group lifted their target price on AnaptysBio from $6.59 to $145.00 and gave the stock a “buy” rating in a research report on Monday, February 19th. SunTrust Banks lifted their target price on AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus lifted their target price on AnaptysBio from $130.00 to $139.00 and gave the stock a “buy” rating in a research report on Tuesday, March 6th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $129.67.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $0.89 million. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. analysts expect that AnaptysBio Inc will post -2.3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “AnaptysBio Inc (ANAB) Holdings Reduced by Perceptive Advisors LLC” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/03/12/anaptysbio-inc-anab-holdings-reduced-by-perceptive-advisors-llc.html.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.